Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Experimental gene therapy treatment used to try to stop most common cause of blindness in aging people on February 18, 2019 at 5:42 pm
(Gray News) – For the first time, a woman with the most common cause of blindness – age-related macular degeneration – has been treated with an experimental gene therapy in the hopes it will halt the ... […]
- What is wet macular degeneration on February 18, 2019 at 12:53 pm
Millions of people deal with age-related macular degeneration as they get older, but many don’t understand the difference between types of the condition or what they can do to lessen the effects. Dr S... […]
- Is a cure for blindness in sight? Scientists launch first attempt to halt most common cause of age-related blindness with gene therapy on February 18, 2019 at 6:36 am
Now the surgeons have launched their first attempt at halting age-related macular degeneration - known as AMD - which is the most common cause of blindness and affects 600,000 people in the UK. The te... […]
- Macular Degeneration on February 17, 2019 at 1:50 pm
Age-related macular degeneration (AMD) is a chronic disease of the macula, the central area of the retina, and is the leading cause of irreversible vision loss in the developed world. AMD is classifie... […]
- Protect Your Aging Eyes From Macular Degeneration on February 15, 2019 at 2:00 pm
FRIDAY, Feb. 15, 2019 (HealthDay News) -- Age-related macular degeneration (AMD) is an incurable eye disease that affects millions of older Americans, but there are a number of things you can do to re... […]
via Google News and Bing News